Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation

Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the efficacy and safety outcomes of this treatment after kidney transplant require confirmation. Methods In a multicenter noninferiority trial, we randomized 2037 de novo kidney transplant recipients to receive, in combi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Am Soc Nephrol
Main Authors: Pascual, Julio, Berger, Stefan P., Witzke, Oliver, Tedesco, Helio, Mulgaonkar, Shamkant, Qazi, Yasir, Chadban, Steven, Oppenheimer, Federico, Sommerer, Claudia, Oberbauer, Rainer, Watarai, Yoshihiko, Legendre, Christophe, Citterio, Franco, Henry, Mitchell, Srinivas, Titte R., Luo, Wen-Lin, Marti, AnaMaria, Bernhardt, Peter, Vincenti, Flavio
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Nephrology 2018
Assuntos:
Clinical Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6050928/
https://ncbi.nlm.nih.gov/pubmed/29752413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2018010009
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares